Mibefradil
Systematic (IUPAC) name | |
---|---|
(1S,2S)-2-(2-((3-(1H-benzo[d]imidazol-2-yl)propyl) (methyl)amino)ethyl)-6-fluoro-1-isopropyl- 1,2,3,4-tetrahydronaphthalen-2-yl 2-methoxyacetate | |
Clinical data | |
AHFS/Drugs.com | Micromedex Detailed Consumer Information |
MedlinePlus | a607007 |
Legal status |
|
Routes of administration | Oral |
Pharmacokinetic data | |
Bioavailability | 70 % |
Protein binding | > 99 % |
Metabolism | Hepatic |
Biological half-life | 17-25 h |
Identifiers | |
CAS Number | 116644-53-2 |
ATC code | C08CX01 |
PubChem | CID 60662 |
IUPHAR/BPS | 2522 |
DrugBank | DB01388 |
ChemSpider | 54673 |
UNII | 27B90X776A |
KEGG | D08217 |
ChEMBL | CHEMBL45816 |
Chemical data | |
Formula | C29H38FN3O3 |
Molar mass | 495.63 g/mol |
| |
| |
Physical data | |
Melting point | 128 °C (262 °F) (dihydrochloride salt) |
(what is this?) (verify) |
Mibefradil (Posicor) is a drug for the treatment of hypertension and chronic angina pectoris. It belongs to a group known as calcium channel blockers.
It is nonselective.[1]
On June 8, 1998, Roche announced the voluntary withdrawal of the drug from the market, one year after approval by the FDA, due to the potential for drug interactions, some of them deadly, which may occur when it is taken together with some other medications. [2]
Synthesis
References
- ↑ Bezprozvanny I, Tsien RW (September 1995). "Voltage-dependent blockade of diverse types of voltage-gated Ca2+ channels expressed in Xenopus oocytes by the Ca2+ channel antagonist mibefradil (Ro 40-5967)". Mol. Pharmacol. 48 (3): 540–9. PMID 7565636.
- ↑ Heart Drug Withdrawn as Evidence Shows It Could Be Lethal: http://www.nytimes.com/1998/06/09/us/heart-drug-withdrawn-as-evidence-shows-it-could-be-lethal.html
This article is issued from Wikipedia - version of the Tuesday, June 16, 2015. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.